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Although the value and limitations of programmed stimula- Table 1. Studies involving <IO patients with noninducible 
tion in the management of patients with coronary disease arrhythmia (13,24) are not listed. Because the role of im- 
and sustained ventricular tachycardia have been reasonably plantable defibrillators in this setting for prevention of sud- 
well established (l-7). the role of programmed stimulation in den dealh is debated, only the rate of sudden death or 
patients with other heart diseases such as congestive cardio- recurrent cardiac arrest is listed. Nonarrhythmic cardiac 
myopathy or hypertrophic cardiomyopathy and sustained deaths that cannot be prevented by defibrillators or antiar- 
ventricular tachycardia is less well established (8-10). Pa- rhythmic agents are not listed. 0ne exception is the current 
tients who survived out of hospital ventricular fibrillation study of Poole et al. (29). in which actuarial rates of sudden 
appear to be different from those with sustained ventricular death ate not reported, but cumulative death rates or ar- 
tachycardia (I I, 12). The role of programmed stimulation in rhythmia-free survival rates are reported. All studies, includ- 
this setting is also less well established (13-29). In a study in ing the current one are limited by i~homoge~eo~s pro- 
this issue of the Journal, Poole et al. (29) analyzed data of grammed stimulation protocols and treatments. Treatments 
241 patients who survived out of hospital ventricular fibril- for patients with noninducible arrhythmia were diverse in 
lation. Their study, the largest one ever published on the these studies mcluding no therapy, surgical and medical 
subject, reveals several important observations and may therapy for ischemia or empiric or “Holter-guided” antiar- 
provide some new insights. rhythmic drug therapy. 
In comparison with patients with sustained ventricular 
tachycatiia, more patients who survived out of hospital 
cardiac arrest do not have inducible ventricular arrhythmias 
by programmed stimulation at baseline. The rate of nonin- 
ducibility varies between 19% and 42% in different studies 
(U-27), perhaps because of different patient groups, stimu- 
lation protocols and definition of nonind;cibility. In general, 
patients with noninducible ventricular arrhythmias have a 
higher ejection fraction and a lower prevalence of coronary 
disease and previous myocardial infarction. The outcome of 
these patients without inducible ventricular arrhythmias is 
controversial. 
Rates of sudden death. Published data regarding the prog- 
nostic significance of baseline inducibility are summarized in 
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In many studies (l4-16,18,22,23), especially the earlier 
ones. actuarial survival calculations were not used. In these 
studies raw rates of sudden death of patients with noninduc- 
ible arrhythmia ranged from 0% to 13% during mean follow- 
up periods of I5 to 38 months, with an exception of the study 
by Roy et al. (la), in which the rate of sudden death of 47 
patients without inducible sustained ventricular tachycardia 
(<30 s in duration) was 32% during a mean follow-up period 
of 24 months. In more recent studies utilizing actuarial 
survival calculations (17,19-21), actuarial rates of sudden 
death of patients with baseline noninducibility of arrhythmia 
at 2 years ranged from 4% to 15%. Higher rates of sudden 
death were reported in patients with baseline arrhythmia 
inducibility. 
Role of left ventricular function. In most studies, includ- 
ing this one, it was reported that baseline noninducibility 
was dssociated with better ventricular function and a lower 
prevalence of coronary disease and previous myocardial 
infarction. In two studies, including the current study 
(20,29), risks of sudden death or cardiac death of patients 
with noninducible arrhythmia were further stratified by left 
ventricular function. Wilber et al. (20) reported that rates of 
recurrent cardiac arrest (including nonfatal cardiac arrest) 
were 8%. 10% and 13% at I, 2 and 3 years, respectively, in 
patients with noninducibility and a high (~30%) ejection 
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Studies 
No. of 
Patients 
~e~~itio~ _. F/‘/u (rno.) 
0iPES PES 
Sadv PES Protocol f-1 (--! PES(-) PES;(-kI PFSl+L 
Rushin et al. (14) 
(abstr) 
Morady et al. (15) 
oy et al. (16) 
Swerdlow et al. (17) 
Skale et al. (23) 
Eldar et al. (I&) 
Kroon et al. ( IYi 
Wilber et al. (20) 
Freedman et al. (21) 
Zeutlin et al. (25) 
Kehoe et al. (22) 
Poole et al. (29) 
NA 
Triple 
Double or triple, 
BRVP 
Triple, 
r triple. 
LVP 
Up to quadruple 
Double and BWVP 
or triple 
Double or triple, 
BRVP 
Double. BRVP 
Up It0 quadruple 
A 
4 be& 
C3U s 
515 beats 
<3 heats 
<6 beats 
~6 beats 
i6 beats 
56 beats 
56 beats 
C6 beats 
83% 
I?% 
15% 
NA 
or 
W.. 42% and WC 
11.2and3yr) 
25% and 35% 
(I and 2 yr) 
NA 
14% 
35% (VT) (2 prF 
29% (VF) (2 yrP 
21% (NSVT) (2 yrP 
18 
20 
17 
NA 
22 
26 
NA 
21 
(median) 
16 
NA 
27 
30 
*Actuarial rat% of recurrent cardiac arrest (not suddem death) o~pat~ents with a high (~30%) or a low (~30%) ejection fraction; tidudes sudden death and 
other cardiac death and all nonfatal recurrences of anRythmias (see texl for details); lactuariarl rates of recurrent cardiac arrest (not sudden death) of patients 
whose inducibility is suppressed or not suppressed. BRVP = bursts of raped ventricular pacing; double = double eht~stimuli; NtJ = can duration o~~ol~~w-up 
except in one study (20) in which a median value was given: NA = I .at available; NSVT = ~onsustait~ed ventricular tachycardia; PES = programmed electrical 
stimulation; PES (-) = ventricular a~bytb~~~a~ noninducible by baseline study;.PES (t 1 = inducible by baseline study; quadruple = quadruple extrastimuli; SCB 
= rate of sudden cardiac death (some rates are estimirtcd from survival curves provided in the text; when actuarial rates are reported. the duration of ollow-up 
is shown underneath in parentheses); triple = triple extrastimuli: VF = ventricular fibrillation: VT = ventricular tachycardia. 
fraction and were 25%, 40% and 44%. res~ective~~~, in 
patients with flo~inducib~~~ty and a bw (~30%) ejection 
fraction. In the current study (29). when patients were 
analyzed by left ventricular function, the cumulative sur- 
vival rates (free of sudden death, aborted sadden death and 
nonsudden cardiac death) in patients with ~o~i~duci~~~ity 
with good ventricular function (ejection fraction >30%) were 
98% and 89% at 1 and 2 years, respectively, and in patients 
with poor ventricular function they were 79% and 64%. 
respectively. The authors (29) id not repor: actuarial rates 
of sudden death. Bn both studi 
inducibility was associated wit 
not an independent predictor of oBtc 
ducibility of ventricular rhythmias represents diverse clin- 
ical outcomes that depand on the programmed stimM~atio~ 
protocol, definition of noninducibility, reversible 
gical therapies and, most i
a better outcome and 
ly, left vemt~cM~~ func- 
coronary disease and is treated me 
prevent ischemia or if reversible es are correct 
true in patients with id 
higher. In patients with nonindMcibi~ity and good ventricular 
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Table 2. Results of Therapy Guided by Programmed Stimulation in Patients With Inducible Ventricular Arrhythmia: Summary of Seven 
Reported Studies 
No. of Patients SCD F/U (l-no.) 
Inducible Efficacy 
Study Arrhythmia Criterion Efficacy Inefficacy Efficacy Inefficacy 
Ruskin et al. (14) 
(abstr) 
Roy et al. (16) 
Skale et al. (23) 
Eldar et al. (18) 
Wilber et al. (20) 
VT or VF (75%) NA 
None (25%) 
VF (8%). VT (53%). <30 s 
NSVT (%I 
None (30%) 
VT, NSVT or <3 beats 
VF (74%) 
None (26%) 
VF (10%). <6 beats 
VT (38%). 
NSVT (21%) 
None (30%) 
VF (IS%,), < IO beats 
VT (37%). 
NSVT (27%) 
None (22%) 
Freedman et al. (21) 
Poole et al. (29) 
VF (15%). 
VT (55%). 
NSVT (15%) 
None (25%) 
VF (16%). 
VT (27%). 
NSVT (14%) 
None (424) 
<6 beats 
<30 s 
36 II 
41 27 
I4 27 
I3 62°F 
91 36 
1 * 
44 48 
5% 36% I8 IS 
15% 19% I8 18 
0% 
8% II% 26 26 
6%. 8% and 14%; 
II. 2 and 3 yr) 
EF = 30% = 3%. 
6% and 15% 
EF < 30% = 14%. 
18% and 22% 
25% II yr) 
25%. 25% and 43%Ei 18%. 33% and M%l 
tl.ZandJyrs) (1. 2 and 3 yrs) 
22% 22 22 
33%. 42% and 56%$ 21 21 
(I. 2 and 3 yr) (median) (median) 
EF z 30% = 24%. 
36% and 46% 
EF < 30% = 43%. 
55% and SS% 
55% (I yr) I6 I6 
30 30 
- 
*Actual number of patients in each goup not provided: tincludes four patirnlr whose ventricular tachycardia became nonsustained: Sincludes nonfatal 
recurrent cardiac arrest; lnumbers include sudden death. other cardiac death and all nonfatal recurrence of arrhythmias. EF = ejection fraction: other 
abbreviations as in Table I. 
function, potential benefits of such therapies should be 
explored; the benefits may not be as dramatic in these 
patients with a relatively low risk of sudden death, although 
the risk of such therapies may also be lower. 
Because ventricular fibrillation could be induced by pro- 
grammed stimulation in some patients without a history of 
malignant ventricular arrhythmias, the specificity of ventric- 
ular fibrillation induced in some clinical settings (30.3 I) or 
any clinical setting (5) has been questioned. However, the 
incidence of ventricular fibrillation induction is usually 
higher in patients with an abnormal heart (5,30,32). In 
addition, the number of extrastimuli required to induce 
ventricular fibrillation in the normal heart is usually higher 
than that required in the abnormal heart (31). 
Incidence of induction of ventricular fibrillation by pro- 
grammed stimulation. The incidence rate is higher in pa- 
tients with a history of cardiac arrest than in patients with 
sustained ventricular tachycardia. It ranges up to 25% in 
various studies (Table 2). The incidence varies in different 
studies probably as a result of differences in programmed 
stimulation protocols, patient groups and definitions of ven- 
tricular fibrillation. Adhar et al. (11) reported that ventricular 
fibrillation was induced in 15 (23%) of 66 survivors of out of 
hospital cardiac arrest, whereas only I (3%) of 35 patients 
with sustained ventricular tachycardia had ventricular fibril- 
lation induced. It appears that although the induction of 
ventricular fibrillation may be a nonspecific finding in some 
patients, there is a significant association between inducibil- 
ity of ventricular fibrillation and a clinical history of cardiac 
arrest. 
Prognosis. Among survivors of cardiac arrest, patients 
with inducible ventricular fibrillation have somewhat better 
ventricular function and a lower prevel,ence of coronary 
disease and previous myocardial infarction as compared 
with patients with inducible sustained ventricular tachycar- 
dia. From this one may expect that patients with inducijle 
ventricular fibrillation have a better outcome than patients 
with inducible sustained ventricular tachycardia. Pn previous 
studies outcomes of these patients were not reported sepa- 
rateiy. Therefore, it is difficult to assess the prognostic 
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ventricular ectopic beats in survivors of cardiac arrest. 
Frequent and complex ventricular ature beats are often 
associated with cardiac arrest an 
t this does not est 
cardiac arrest an 
beats. 
studied the role of programmed 
therapy of survivors of sudden 
arrhythmias by programmed sti 
are summarized in Table 2. Studies involving ~10 patients in 
either group (suppressed inducibility group or nonsup- 
pressed group) and those in which the outcome of patients 
with inducibility was not separately reported according to 
the suppression of inducibilit are not listed. Results are 
diverse, probably because of iRerent patient groups and 
efficacy criteria, as well as the different therapies used. In 
general, the suppressed inducibiiity group received drug 
therapy (mostly class I antiarrhythmic agents) or surgical 
therapy (coronary bypass surgery or endocardial resection). 
The nonsuppressed group was primarily treated with amio- 
darone in some studies (15.18). In other studies various 
medical and surgical tkerapies including an implantable 
automatic defibrillator were used. Some investigators 
(14.20.23) have reported an excellent outcome in patients 
whose inducible arrhythmia is suppressed by therapy. They 
have also reported a marked difference between outcomes of 
patients with suppressed and nonsuppressed inducibility. 
s~~~i~ca~ce of ventricular f~~~ct~o~ i 
ible arrbytbm~a was suppressed by 
agents. The 2 year survival rate was 7 
others (14.21.23). 
defined iis no i~ducjbl~~ sustained (>30 s) ventric 
. induction of ~ons~sta~~ed ventricular ta 
ion of 6 beats to 30 s) was considered 
ecause the duration of nonsustained ventricular tachycar- 
rogrammed stimulation during therapy may 
significance (6,7,17), the inclusion of pa- 
tients with a long nonsustained ntricular tachycardia (for 
example. 2 15 beats) induced by ogrammed stimulation in 
the suppressed inducibility gro ould have worsened the 
outcome in this group. 2) As a result of this efficacy criterion. 
therapy of patients with inducible nonsustained ventricular 
tachycardia at baseline was not guided by programmed 
stimulation. The exclusion of patients with inducible nonsus- 
tained ventricular tachycardia may have reduced the predic- 
tive value by increasing the proportion of patients with 
inducible ventricular fibrillation among those (’ 
was guided by programmed stimulation. Su 
inducible ventricular fibril~at~oo may not be 
marker for therapeutic e 
patients in the nonsuppressed i~d~cibi~ity 
amiadarone and most patients in the su 
received class I agents. This difference in therapy may have 
influenced the outcome of the suppressed and nonsup- 
pressed groups in this study. in a study by Wilber et al. (201 
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amiodarone was given to 34% of the patients with nonsup- 
pressed inducibility as compared with 71% in the Current 
study (27) and to 13% of the patients with suppressed 
inducihility as compared with none in the current study. This 
may explain a relatively poor outcome of patients with 
nonsuppressed in ucibility inthe study by Wilber et al. (20) 
and a relatively good outcome of patients with nonsup 
pressed inducibility in the current study (27). 
4) Poole et al. (29) excluded patients who had sustained 
ventricular tachycardia initially that subsequently degener- 
ated to ventricular fibrillation. Because most ventricular 
fibrillation starts as ventricular tachycardia, the initial doc- 
umented rhythm may depend on the arrival time of the 
paramedical personnel. There may not be any practical nd 
clinical differences between patients with an initial docu- 
mented rhythm of ventricular fibrillation and patients with 
initial ventricular tachycardia that degenerates o ventricular 
fibrillation after the paramedics arrive. The arbitrary exclu- 
sion of these survivors of cardiac arrest may have influenced 
the results of the study. 
S of suppression of inducible ventri fibrilla- 
tion. Other investigators have also reported somewhat disap- 
pointing outcomes in patients whose inducible arrhythmia w s 
suppressed by class I agents (15.18.21) and good outcomes in
patients reated with amiodarone (15.18). Wilber et al. (20), 
who repotted that inducibility atthe time of discharge was an 
independent predictor foutcome, also reported a disappoint- 
ing outcome inpatients with suppression f inducibility and a 
low ejection fraction. Therefore. it appears that he negative 
predictive value and sensitivity of programmed stimulation 
may be less good in survivors ofcardiac arrest than in patients 
with sustained ventricular tachycardia. 
The reason for this difference is unclear, although postu- 
lations have been made (36,37). An arrhythmogenic matrix 
(36,37) may not be fixed in many survivors of cardiac arrest 
and may be transiently deformed by autonomic changes, 
ischemia, pH changes, mechanical stretch, drug toxicity, 
electrolyte imbalances or acute hemodynamic changes. Pro- 
grammed stimulation may not be suitable for prediction of 
drug efficacy during a transient perturbation f the arrhyth- 
mogenic matrix (36,37). The mechanism of ventricular fibril- 
lation induced by programmed stimulation is probably dif- 
ferent from the mechanism of clinical ventricular fibrillation 
in many instances (35). Ventricular fibrillation by pro- 
grammed stimulation is often induced with closely coupled 
(< 180 m?) extrastimuii (38). Class IA agents may prevent the 
induction of this ventricular fibrillation by prolonging the 
refractory period of the ventricle at the site of stimulation 
without significantly affecting ventricular fibrillation thresh- 
old or electric instability of the entire heart (6). Conse- 
quently, a class IA agent may be considered effective by 
programmed stimulation criteria even if it may not have 
significant elects on the entire myocardium. In addition, 
life-threatening proarrhythmia (especially torsade de pointes 
from Class IA agents) by antiarrhythmic drugs cannot be 
reliably predicted by programmed stimulation. Ambu~~to 
electrocardiographic monitoring and exercise testing may be 
useful in predicting proarrhythmia in some instances (39). 
Patients with suppression f inducibility may die as a result 
of proarrhythmia. Patients with poor ventricular function 
who often have electrolyte imbalances are at high risk of 
life-threatening proarrhythmia. 
Yhf -refore, suppression of inducible ventricular fibrilla- 
tion i;ray not be as useful in guiding therapy as is suppres- 
sion of ve~~ric~~l~~ tac~zy~ardia induced by programmed 
stimulation (53). In the current stu 
one half of patients whose therapy was guided by pro- 
grammed stimulation had mducibIe ventricular fib~l~ation. 
This may have influenced the outcome of the suppressed 
inducibility group. A separate analysis of patients with 
inducible ventricular tachycardia and ventricular fibrillation 
is needed to address this important issue. 
As suggested bythe study of Poole et al. (29) and others, 
the results of treatment with class I antia~hytbmic agents 
are somewhat disappointing. The outco 
treated with amiodarone is not separately reported in their 
study. Amiodarone appears to be quite effective in some 
reports although its effect is debated inothers. Eldar et al. 
(18) reported rates of sudden death of 6% during a follow-up 
of 26 months. In so e patients cardiac surgery, especially 
coronary bypass urgery, is associated with good results 
(20,22). 
Implantable defibrillator thera atients with b~el~me 
nonlnducibility. An implantable d fibrillator is often recom- 
mended for patients with sustained ventricular tachycardia 
or fibrillation without baseline arrhythmia nducibility, al- 
though no controlled studies have been done. To address the 
issue, one has to consider risks (including surgical mortality) 
and benefits of defibrillator therapy and risks of sudden 
death in these patients. In the current study of Poole et al. 
(29) 4 (12%) of 34 patients treated with an implantable 
defibrillator died suddenly, an additional 4 patients (12%) 
had nonsudden death and 7 patients (21%) had a nonfatal 
recurrence (discharges from the defibrillator) during the 30 
months of follow-up. Although the results are somewhat 
different from some studies, especially a study (40) done 
with data compiled by a manufacturer of defibrillators, 
others (41-43) have reported results imilar to the curent 
study. Veltri et al. (41) reported that the surgical mortality 
rate in a large series after implantation of an automatic: 
defibrillator was 5% and the actuarial rate of sudden death 
was 4% after 2 years. When this is compared with 
published (20) outcome of patients with ~~~~~d~cib~e v 
tricular arrhythmia and a low ejection fraction, it appears 
appropriate to treat hese patients with defibrillator therapy. 
Patients with noninducibility and a high ejection fraction, 
however, have a rate of sudden death of about I 10% after 2 
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e that the results 
published data. With further development of de~bri~~ator 
technology, morbidity and mortality of I 
decrease and efficacy will increase. The role o 
therapy will increase further iw the future. 
present the utillity of the therapy s 
in various clinical settings with cons~ 
The role of programmed stiml~lation in t 
of survivors of cardiac arrest may be different from that in 
patients with sustained ~~e~tricolar tachycardia. ~~tbou~ 
noninducibility of ventricular arrhythmia at baseline is usu- 
ally associated with a better ventricular function and a lower 
prevalence of previous myocardial infarction, left ventricu- 
lar function is a more important predictor of outcome. 
Noninducibility in patients with a poor ventricular function 
is associated with a poor outcome. Therapeutic approaches 
such as defibrillator therapy (411-43, amiodarone (181 or 
noninvasive approaches (6,45-481) should be used singly or 
in conjunction in these patients. ~oni~d~cibility in patients 
with a good ventricular function is associated with a favor- 
able outcome. The role of other approaches (6,~~.4~-4~~ 
should be explored in this setting. 
Inducible ventricular fibrillation in survivors of cardiac 
arrest may have a prognostic significance. However. sup- 
pression of inqkible ventricular fibrillation with drug ther- 
risks of the currently available de~br~~~at~~ 
tccb~o~o~~. 
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